# Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
Canonical URL: https://biopharmsignal.com/news/PHVS/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026-f5146f6d
Ticker: PHVS
Company: Pharvaris
Source: Pharvaris
Published: 2026-05-29 10:50 EST
## Summary

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2...

## Article Body
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk/poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026 , to be held from June 12-15, 2026, in Istanbul, Turkey.

Details of the presentations are as follows:

Title: Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: End of Progression Results in the Phase 3 RAPIDe-3 Trial Presenter: Mauro Cancian, M.D., Ph.D. Format: Oral Presentation Date, time: Friday, June 12, 2026, 3:00-4:30 p.m. TRT (8:00-9:30 a.m. EDT)

Title: Clinical Cardiovascular Safety Assessment of Oral Deucrictibant Presenter: Anne Lesage, Ph.D. Format: Poster Presentation Date, time: Friday, June 12, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT)

Title: A Clinically Validated Kinin Biomarker Assay to Differentiate Bradykinin-Mediated from Mast Cell-Mediated Angioedema Presenter: Evangelia Pardali, Ph.D. Format: Poster Presentation Date, time: Friday, June 12, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT)

Title: Evaluations of Safety Margins and Response to Deucrictibant Extended-Release (XR) Tablet in Combination with Deucrictibant Immediate-Release (IR) Capsule Presenter: Anne Lesage, Ph.D. Format: Poster Presentation Date, time: Saturday, June 13, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT)

Title: Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial Presenter: Philip Li, M.D., FRCP Format: Poster Presentation Date, time: Saturday, June 13, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT)

Title: RAPIDe-3 Patient Voices: Qualitative Insights from the Phase 3 Study of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks Presenter: Anna Valerieva, M.D., Ph.D. Format: Poster Presentation Date, time: Saturday, June 13, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT)

Title: Results of the Phase 2 CHAPTER-1 Open-Label Extension Study on the Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema Presenter: Markus Magerl, M.D. Format: Flash Talk Date, time: Saturday, June 13, 2026, 3:00-4:30 p.m. TRT (8:00-9:30 a.m. EDT)

Title: CHAPTER-1 Open-Label Extension Study: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema Presenter: Markus Magerl, M.D. Format: Flash Talk Date, time: Saturday, June 13, 2026, 3:00-4:30 p.m. TRT (8:00-9:30 a.m. EDT)

The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: ir.pharvaris.com/news-events/events-presentations .

About Pharvaris Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. Pharvaris is preparing marketing authorization applications for deucrictibant immediate-release capsule as an on-demand treatment of HAE attacks, and a global pivotal Phase 3 study of deucrictibant extended-release tablet for the prevention of HAE attacks (CHAPTER-3) is ongoing with topline data anticipated in the third quarter of 2026. In addition, CREAATE is an ongoing Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks. For more information, visit https://pharvaris.com/.
## Recent Company News
- 2026-07-22 10:50 EST — [Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema](https://biopharmsignal.com/news/PHVS/publication-in-clinical-reviews-in-allergy-immunology-summarizes-decades-of-evid-a202e0d7) — Source: Pharvaris
- 2026-07-06 10:50 EST — [Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks](https://biopharmsignal.com/news/PHVS/pharvaris-announces-fda-acceptance-of-new-drug-application-for-deucrictibant-ir--11e9782b) — Source: Pharvaris
- 2026-06-15 10:50 EST — [Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026](https://biopharmsignal.com/news/PHVS/data-supporting-differentiated-profile-of-deucrictibant-in-hae-management-presen-1a36672e) — Source: Pharvaris
- 2026-06-11 10:50 EST — [Pharvaris Announces Annual General Meeting of Shareholders](https://biopharmsignal.com/news/PHVS/pharvaris-announces-annual-general-meeting-of-shareholders-d8f6d597) — Source: Pharvaris
- 2026-05-29 10:50 EST — [Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026](https://biopharmsignal.com/news/PHVS/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026-f5146f6d) — Source: Pharvaris
## Related News
- 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a)
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)